

# The Island Capsule

PEI College of Pharmacists

9/9/2016

Edition 2, Volume 35

## *Education Event- Moving The Mountain, with Marshall Moleschi*

The PEI College of Pharmacists, in partnership with the Ontario College of Pharmacists, is pleased to announce that Marshall Moleschi, Registrar of the Ontario College of Pharmacists (OCP) will present Moving the Mountain. This presentation will detail the efforts made by OCP to ensure members practice to the standard of practice. The presentation will be held on Friday, September 16, 2016 beginning 6:30 pm at the Holiday Inn Express on Capital Drive, Charlottetown. The PEI College of Pharmacists has awarded 1.5 CEUs for this event and it is open to all pharmacists and pharmacy technicians. **Please RSVP** for this event by emailing [info@pepharmacists.ca](mailto:info@pepharmacists.ca) by Wednesday September 14, 2016. Refreshments will be served.

### MISSION

*Regulating the practice of pharmacy in the province so as to promote a high standard and safeguard the welfare of the public with regard to pharmaceutical service.*

## *Drug Schedule Changes*

In April of this year, recommendations made by NAPRA's National Drug Scheduling Advisory Committee (NDSAC) regarding modified-release ibuprofen and esomeprazole were finalized and said to be in effect subject to removal from the Prescription Drug List (PDL). On August 18, 2016 these drugs

## *College Elects New Council Member*

The PEI College of Pharmacists would like to announce that Jeff Jardine has been elected by acclamation to Council. Jeff will replace Bonnie Corish as her term on Council comes to an end October 1, 2016. The Council will request his appointment by the Minister of Health and Wellness. Jeff brings previous experience from the PEI Pharmacy Board as well as on National committees. The Council welcomes Jeff into his new role.



# The Island Capsule

PEI College of Pharmacists

9/9/2016

Edition 2, Volume 35

in the specific dosages and package sizes (if applicable) as recommended by NDSAC were removed from the PDL by Health Canada and are now in effect as follows:

- ibuprofen or its salts, when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit – is granted Schedule III status.
- esomeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole – is granted Schedule II status.